Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Adcock
INDICATIONS [/za_100.html#1] [/za_100.html#1] [/za_100.html#1] CONTRA-INDICATIONS [/za_100.html#1] [/za_100.html#1] DOSAGE [/za_100.html#1] [/za_100.html#1] SIDE-EFFECTS [/za_100.html#1] [/za_100.html#1] [/za_100.html#1] PREGNANCY [/za_100.html#1] [/za_100.html#1] OVERDOSE [/za_100.html#1] IDENTIFICATION [/za_100.html#1] [/za_100.html#1] PATIENT INFORMATION ADCO-DOXAZOSIN 1 MG TABLETS ADCO-DOXAZOSIN 2 MG TABLETS ADCO-DOXAZOSIN 4 MG TABLETS SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): ADCO-DOXAZOSIN 1 MG TABLETS ADCO-DOXAZOSIN 2 MG TABLETS ADCO-DOXAZOSIN 4 MG TABLETS COMPOSITION: Each 1 mg, 2 mg and 4 mg ADCO-DOXAZOSIN tablet contains DOXAZOSIN mesylate equivalent to 1 mg, 2 mg and 4 mg free base respectively. PHARMACOLOGICAL CLASSIFICATION: A 7.1 Vasodilators, hypotensive medicines. PHARMACOLOGICAL ACTION: Doxazosin mesylate is a quinazoline derivative, with the chemical name: 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxan-2-yl) carbonyl]piperazine monomethanesulphonate. ADCO-DOXAZOSIN is a selective postsynaptic alpha 1 -adrenoceptor antagonist. Blockade of this receptor causes vasodilatation, decrease in peripheral resistance and decrease in blood pressure. Doxazosin therapy is accompanied by little or no reflex tachycardia. ADCO-DOXAZOSIN is well absorbed after oral administration, and peak plasma concentration levels of Doxazosin occur after approximately 2 hours. The plasma elimination half-life is biphasic with a mean terminal half-life of approximately 19 to 22 hours, hence providing the basis for once-daily dosing. ADCO-DOXAZOSIN is extensively metabolised in the liver with less than 5% of the unchanged medicine excreted in the faeces. The metabolites are mainly excreted via the faeces. Following an oral dose, maximum reductio Read the complete document